Heart Failure
Conditions
Interventions
Vericguat treatment group:None
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Fully understand the purpose and requirements of this study, sign the informed consent form, and have good compliance. 2. Participants who meet the following conditions: (1). Participants aged 18 and above; (2). Have been clearly diagnosed with heart failure, meet the diagnostic criteria for heart failure, NYHA>=II level; (3). Received Vericiguat treatment during 2021-2024, and the treatment time is not less than 1 month; (4). Can provide complete medical records, including treatment plans, medication information, clinical course, etc.
Exclusion criteria
Exclusion criteria: 1.Participants who have undergone heart transplantation or are waiting for heart transplantation; 2.Participants with severe end-stage organ diseases, such as severe liver and kidney failure, etc. 3.Participants with severe other cardiovascular events, such as acute coronary syndrome, stroke, etc. 4.Participants with active cancer or undergoing cancer treatment; 5.Participants with severe immune system diseases, such as systemic lupus erythematosus, rheumatoid arthritis, etc. 6.Participants with severe mental illness or cognitive impairment, affecting treatment compliance and data collection capabilities; 7.Participants who have received other clinical trial treatments within 3 months before the start of the study; 8.Participants who are allergic to Vericiguat or related drugs; 9.Participants using other sGC stimulants; 10.Participants who cannot provide complete medical records or key information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP;LVEF;LVDd;NYHA class;Main outcome events (Emergency treatment due to heart failure, readmission due to heart failure, death due to heart failure, and all-cause mortality events); | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality;Blood Pressure;Creatinine; | — |
Countries
China
Contacts
Public ContactAilan Chen
The First Affiliated Hospital of Guangzhou Medical University
Outcome results
None listed